DiaSorin SpA
MIL:DIA
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
83.3
110.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
DiaSorin SpA
DiaSorin SpA
Cost of Revenue
DiaSorin SpA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaSorin SpA
MIL:DIA
|
Cost of Revenue
-€408.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
El En SpA
MIL:ELN
|
Cost of Revenue
-€395.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
DiaSorin SpA
Glance View
DiaSorin SpA is a prominent Italian diagnostic solutions provider that has carved a niche in the healthcare industry. Founded in 1968, the company specializes in developing and manufacturing innovative diagnostic tests that facilitate disease detection, monitoring, and prevention. With a robust portfolio that ranges from immunodiagnostics to molecular diagnostics, DiaSorin has made significant strides in addressing urgent healthcare needs. The company operates globally, serving hospitals and laboratories across numerous countries, and has established a strong commitment to research and development. This focus not only enhances their product offerings but also positions them as a key player in rapidly evolving sectors like infectious disease testing, oncology, and autoimmune disorders. For investors, DiaSorin presents an intriguing opportunity rooted in its strategic growth initiatives and resilience amid market challenges. The company's strong track record of revenue growth and profitability, coupled with its agile response to emerging health crises—such as the COVID-19 pandemic—highlights its operational efficiency and adaptability. Furthermore, with an ongoing emphasis on expanding its product lines and seeking partnerships to drive innovation, DiaSorin is well positioned to capitalize on the increasing demand for advanced diagnostic solutions. As healthcare continues to evolve with technological advances and personalized medicine, DiaSorin’s capabilities and strong market presence make it a compelling consideration for investors looking for sustainable growth in the life sciences sector.
See Also
What is DiaSorin SpA's Cost of Revenue?
Cost of Revenue
-408.6m
EUR
Based on the financial report for Jun 30, 2024, DiaSorin SpA's Cost of Revenue amounts to -408.6m EUR.
What is DiaSorin SpA's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-14%
Over the last year, the Cost of Revenue growth was 3%. The average annual Cost of Revenue growth rates for DiaSorin SpA have been -8% over the past three years , -14% over the past five years .
You don't have any saved screeners yet
